Leading Independent Proxy Advisory Firm ISS Recommends Shareholders Vote “FOR” All of Crown Castle’s Director Nominees
May 13, 2024 07:30 ET
|
Crown Castle Inc.
HOUSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today announced that Institutional Shareholder Services (ISS), a leading independent proxy...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024 07:30 ET
|
MiNK Therapeutics
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board...
Alaska Energy Metals Advances Core Asset Focus With Sale of Mexico Subsidiary and Shareholding
May 13, 2024 07:30 ET
|
Alaska Energy Metals Corporation
VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) today announced: The sale of its shareholding in...
Enovix Begins Customer Sampling of EX-1M Batteries
May 13, 2024 07:30 ET
|
Enovix Corporation
FREMONT, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced that it has begun customer sampling of its...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
May 13, 2024 07:30 ET
|
BridgeBio Pharma, Inc.
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality...
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
May 13, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Akoustis Reports Third Quarter FY24 Results
May 13, 2024 07:30 ET
|
Akoustis, Inc.
Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support...
Spectral Medical Announces First Quarter Results and Provides Corporate Update
May 13, 2024 07:30 ET
|
Spectral Medical Inc.
Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – –...
HydroGraph to Host Investor Webinar, Attend Upcoming Conferences
May 13, 2024 07:30 ET
|
Hydrograph Clean Power Inc.
TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGCPF) (the “Company” or “HydroGraph”), a commercial manufacturer of pristine graphene, announced it will host...
- June 17, 2024 06:07 ET Global Student Loan Market Report 2024: Market Value to Reach $3,800 Billion by 2029 - Student Loans Continue to Rise Across All Demographics
- June 17, 2024 06:00 ET Wawa’s Hoagiefest® is Back with $5 Shortis and $6 Classics and Four Additional Weeks of Savings! “Kelce Classics;” Add Fun and a Nod to How Jason and Kylie Order Their Hoagies!